The Use of Exenatide in Islet Transplant Recipients with Chronic Allograft Dysfunction: Safety, Efficacy and Metabolic Effects

BACKGROUND: A current limitation of islet transplantation is reduced long term graft function. The glucagon like peptide-1 (GLP-1) receptor agonist, exenatide (Byetta(®), Amylin Pharmaceuticals, CA) has properties that could improve existing islet function, prevent further loss of islet mass and pos...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Froud, Tatiana, Faradji, Raquel N., Pileggi, Antonello, Messinger, Shari, Baidal, David A., Ponte, Gaston M., Cure, Pablo E., Monroy, Kathy, Mendez, Armando, Selvaggi, Gennaro, Ricordi, Camillo, Alejandro, Rodolfo
Médium: Artigo
Jazyk:Inglês
Vydáno: 2008
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2772201/
https://ncbi.nlm.nih.gov/pubmed/18622276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/TP.0b013e31817c4ab3
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky